Abstracts tagged "Cardiovascular disease and rheumatic disease"

Abstract Number: 2132 • 2019 ACR/ARP Annual Meeting
Complement Component 3 as Biomarker of Cardiometabolic Risk in Rheumatic Diseases: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Systemic Lupus Erythematosus
Ivan Arias de la Rosa¹, Alejandro Escudero ², Maria Dolores Lopez-Montilla ³, Maria del Carmen Abalos-Aguilera ³, Alejandro Ibañez-Costa ³, Carlos Perez-Sanchez ⁴, Rocío Segura-Ruiz ⁵, Alejandra Patiño-Trives ³, Maria Luque-Tevar ³, Carmen Torres-Granados ¹, Rafaela Ortega ³, Maria Carmen Castro ³, Jerusalem Calvo-Gutierrez ³, Pilar Font ¹, Mª Ángeles Aguirre-Zamorano ², Eduardo Collantes-Estevez ¹, Chary Lopez-Pedrera ³ and Nuria Barbarroja ⁶, ¹University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁵Reina Sofia University Hospital/IMIBIC, Córdoba, Spain, ⁶University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain
Background/Purpose: Patients with rheumatic diseases have an increased risk of cardiovascular disease (CVD). Cardiometabolic disease includes an alteration in metabolic organs and CV system that…
Abstract Number: 1405 • 2013 ACR/ARHP Annual Meeting
Expression Of High Mobility Group Protein B1 and Its Receptors In Heart Of Patients With Coronary Artery Disease With and Without Inflammatory Rheumatic Disease: A Biopsy Study
Mei Zong¹, Ivana Hollan², Huiyuan Xiao³, Cecilia Grundtman⁴, Eva Lindroos⁵, Helena E. Harris⁶, Knut MIkkelsen⁷, Stein E. Rynning⁷, Sven M. Almdahl⁸ and Ingrid E. Lundberg⁹, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ³University of Oxford, Oxford, United Kingdom, ⁴Innsbruck Medical University, Innsbruck, Austria, ⁵Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁶Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁷Feiring Heart Clinic, Feiring, Norway, ⁸Cardiothoracic surgery, University Hospital of North Norway, Tromsø, Norway, ⁹Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) have increased risk of morbidity and mortality in coronary artery disease (CAD) compared to the general population. High…
Abstract Number: 1018 • 2013 ACR/ARHP Annual Meeting
Methodology Of Determining An Appropriate Look-Back Period To Identify Autoimmune Rheumatic Disease In a Study Of Post-Myocardial Infarction Mortality
Mark Tacey, Megan Bohensky and Sharon Van Doornum, Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia
Background/Purpose: Hospital administrative datasets offer an opportunity to study the relatively rare occurrence of auto-immune rheumatic diseases (AIRD). Under-coding is a known limitation however. “Look-back”…
Abstract Number: 781 • 2013 ACR/ARHP Annual Meeting
Mortality Rates, Readmissions and Revascularisation Following a First Myocardial Infarction In Patients With Autoimmune Rheumatic Disease Compared With Controls
Sharon Van Doornum^1,2, Megan Bohensky¹, Mark Tacey¹, Caroline Brand^1,3, Vijaya Sundararajan⁴ and Ian Wicks⁵, ¹Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia, ²Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ³Melbourne EpiCentre, The Royal Melbourne Hospital, Melbourne, Australia, ⁴Medicine, University of Melbourne, Melbourne, Australia, ⁵Rheumatology Unit, Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: We have previously demonstrated increased case fatality following myocardial infarction (MI) in rheumatoid arthritis (RA) patients[1], however post-MI case fatality has not been investigated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].